Inhibition of antagonist and agonist binding to the human brain muscarinic receptor by arachidonic acid.
Arachidonic acid (AA) inhibits the binding of [3H]quinclidinyl benzilate ([3H]QNB) to the human brain muscarinic cholinergic receptor (mAChR). AA inhibits at lower concentrations in the absence of glutathione (I50 = 15 microM) than in the presence of glutathione (I50 = 42 microM). Inhibition of mAChR binding shows specificity for AA and is reduced with loss of one or more double bonds or with either a decrease or increase in the length of the fatty acid chain. Metabolism of AA by the lipoxygenase, epoxygenase, or fatty acid cyclooxygenase pathways is not required for the inhibitory activity of AA on mAChR binding. Inhibition of [3H]QNB binding by AA is reversible. While decreasing Bmax, AA increased the apparent KD for [3H]QNB and for the more polar antagonist [3H]NMS. In addition, AA inhibits binding of the agonist [3H]oxotremorine-M (I50 = 60 microM) and is the first mediator of mAChR action to be shown to reversibly inhibit mAChR binding. The feedback inhibition of the mAChR by AA may serve a homeostatic function similar to the reuptake and hydrolysis of acetylcholine following cholinergic nerve transmission.
Kjome
J R
JR
Department of Neurology, Alzheimer's Treatment and Research Center, HealthPartners, Regions Hospital, St. Paul, MN 55101-2595, USA.
Swenson
K A
KA
Johnson
M N
MN
Bordayo
E Z
EZ
Anderson
L E
LE
Klevan
L C
LC
Fraticelli
A I
AI
Aldrich
S L
SL
Fawcett
J R
JR
Venters
H D
HD
Ala
T A
TA
Frey
W H
WH
D000328:Adult; D001095:Arachidonic Acids / Q000378:metabolism / Q000494:pharmacology*; D002839:Chromans / Q000494:pharmacology; D005227:Fatty Acids / Q000378:metabolism / Q000494:pharmacology; D005246:Feedback; D005625:Frontal Lobe / Q000378:metabolism; D005978:Glutathione / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008345:Manganese / Q000494:pharmacology; D018721:Muscarinic Agonists / Q000378:metabolism*; D018727:Muscarinic Antagonists / Q000378:metabolism*; D019832:N-Methylscopolamine / Q000378:metabolism; D010095:Oxotremorine / Q000031:analogs & derivatives / Q000378:metabolism; D019308:Palmitic Acid / Q000494:pharmacology; D011813:Quinuclidinyl Benzilate / Q000378:metabolism*; D011976:Receptors, Muscarinic / Q000378:metabolism*
D001095:Arachidonic Acids; D002839:Chromans; D005227:Fatty Acids; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; D019308:Palmitic Acid; D008345:Manganese; D010095:Oxotremorine; C042743:oxotremorine M; D011813:Quinuclidinyl Benzilate; D005978:Glutathione; C010643:6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; D019832:N-Methylscopolamine